Reactive perforating collagenosis successfully treated with dupilumab
Open Access
- 28 May 2022
- journal article
- letter
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 63 (3) , 398-400
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with ADImmunity, Inflammation and Disease, 2021
- Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to responseJournal of Dermatological Treatment, 2020
- Clinical practice guide for the treatment of perforating dermatosisThe Journal of Dermatology, 2020
- Dupilumab for prurigo nodularis: Case series and review of the literatureDermatologic Therapy, 2020
- Acquired reactive perforating dermatosisJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2013